DDInter1611 DDInter1376
Rizatriptan is a second-generation triptan and a selective 5-HT<sub>1B and 5-HT1D</sub> receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Rizatriptan {u} (Compound) resembles {v} (Compound) Sumatriptan
Rizatriptan {u} (Compound) binds {v} (Gene) HTR1D
Rizatriptan {u} (Compound) palliates {v} (Disease) migraine
Rizatriptan {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 1d Receptor Agonists
Rizatriptan {u} (Compound) causes {v} (Side Effect) Vasospasm
Rizatriptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Rizatriptan {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Rizatriptan {u} may lead to a major life threatening interaction when taken with {v} Granisetron
Rizatriptan (Compound) resembles Sumatriptan (Compound)
Rizatriptan (Compound) binds HTR1D (Gene)
Rizatriptan (Compound) palliates migraine (Disease)
Rizatriptan (Compound) is included by Serotonin 1d Receptor Agonists (Pharmacologic Class)
Rizatriptan (Compound) causes Vasospasm (Side Effect)
Rizatriptan may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Rizatriptan may lead to a major life threatening interaction when taken with Methylene blue
Rizatriptan may lead to a major life threatening interaction when taken with Granisetron